Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, ...

Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late024.

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. Published first on TheFly – the ultimate source for ...

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stokholders of Opus Genetics. Ocuphire insiders ...

Ocuphire Pharma (Nasdaq: OCUP) has announced the acquisition of Opus Genetics, a clinical-stage gene therapy company focused ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Traders use this information to analyze potential trades and assess market sentiment for Ocuphire Pharma. In The Money Expiration Date October 18, 2024 November 15, 2024 December 20, 2024 February ...

Ocuphire Pharma meanwhile has a pilocarpine and phentolamine combination that it says could improve vision at a lower dose, avoiding side effects. Phentolamine acts as a pupil dilator. It's a ...